Merck Offers Update On Phase 3 KEYNOTE-062 Trial Evaluating KEYTRUDA® as Monotherapy, In Combination with Chemotherapy for First-Line Treatment of Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma